Moderna, Inc. (MRNA) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Cambridge, MA, United States. Le PDG actuel est Stéphane Bancel.
MRNA a date d'introduction en bourse 2018-12-07, 5,800 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $21.43B.
Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The company's portfolio spans multiple therapeutic areas including infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases, with products marketed across the United States, Europe, and internationally. Moderna's vaccine pipeline includes respiratory vaccines such as COVID-19 and influenza, latent vaccines targeting viral infections like HIV and cytomegalovirus, and cancer vaccines including personalized and KRAS-directed therapies. The company maintains strategic partnerships with leading pharmaceutical and biotech firms including Merck, AstraZeneca, Vertex Pharmaceuticals, and collaborates with governmental and philanthropic organizations such as BARDA and The Bill & Melinda Gates Foundation. Founded in 2010 and rebranded as Moderna, Inc. in 2018, the company continues to advance mRNA-based solutions across multiple disease areas.
